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Abstract: At present, Lupus Nephritis (LN) is still awaiting a biomarker to better monitor disease
activity, guide clinical treatment, and predict a patient’s long-term outcome. In the last decade, novel
biomarkers have been identified to monitor the disease, but none have been incorporated into clinical
practice. The transmembrane receptor neuropilin-1 (NRP-1) is highly expressed by mesangial cells
and its genetic deletion results in proteinuric disease and glomerulosclerosis. NRP-1 is increased
in kidney biopsies of LN. In this work we were interested in determining whether urinary NRP-1
levels could be a biomarker of clinical response in LN. Our results show that patients with active LN
have increased levels of urinary NRP-1. When patients were divided according to clinical response,
responders displayed higher urinary and tissue NRP-1 levels at the time of renal biopsy. Areas
under the receiver operating characteristic curve, comparing baseline creatinine, proteinuria, urinary
NRP-1, and VEGFA protein levels, showed NRP-1 to be an independent predictor for clinical response.
In addition, in vitro studies suggest that NRP-1could promote renal recovery through endothelial
proliferation and migration, mesangial migration and local T cell cytotoxicity. Based on these results,
NRP-1 may be used as an early prognostic biomarker in LN.
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1. Introduction
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with a broad
spectrum of manifestations and organ involvement [1,2]. Lupus nephritis (LN) affects up to 50% of
patients with SLE and is a major cause of morbidity, despite modern therapeutic approaches [2,3].
To date, renal biopsy is still the gold standard for diagnosing and classifying the degree of renal
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inflammation and scarring, but its invasiveness makes it unsuitable for serial monitoring. Conventional
clinical parameters are not sensitive or specific enough for detecting ongoing disease activity, early
relapse, disease progression, or response to therapy [2–4]. In recent years there has been increasing
interest in developing novel biomarkers; however, few of them have been rigorously validated in large
scale longitudinal studies, none have been standardized for daily clinical practice, and mainly they
had been assessed for their potential as “diagnostic biomarkers”.
Neuropilin-1 (NRP-1) was originally identified as co-receptor for class 3 semaphorins, a family
of molecules involved in axon repulsion [5]. Besides its critical role during embryogenesis, NRP-1
has important functions in adult tissues, being involved in axonal guidance, vascular endothelial
sprouting, regeneration organ repair and immunosuppression. Evidence suggests that its role as
immune-regulator would be in mediating interactions between activated dendritic cells and resting T
cells [6–13], and promoting regulatory T cell activity [11].
Although originally detected in neurons, NRP-1 is also expressed in non-neural cells including
epithelial and endothelial cells, where it also acts as a receptor for several members of the vascular
endothelial growth factor (VEGF) family, enhancing signaling and promoting angiogenesis [14–16].
Other ligands include hepatocyte growth factor, platelet-derived growth factor BB, transforming
growth factor-β1 (TGF-β1), and fibroblast growth factor2 (FGF2) [17,18]. In addition, it has been found
that NRP-1 is present on cultured human mesangial cells and with the presence of VEGF play an
important role in mesangial cell pathophysiology [19].
Little is known about the involvement of NRP-1 in SLE, and its role in lupus nephritis. Decreased
NRP-1 and SEMA3A expression on serum B cells from patients with SLE has been described [20,21].
Vasdaz et al. in a study including 12 patients with LN showed an increased renal expression of NRP-1
in deposits found only in the damaged glomerular areas correlated with proteinuria and chronicity
index (endothelial damage) [22]. So far, there are no studies evaluating NRP-1 as a biomarker of LN.
Our aim was to evaluate expression levels of NRP-1 at the time of the renal biopsy in patients with LN
and determine their predictive value for nephritis therapy response.
2. Results
2.1. Patients
A total of seventy patients with active LN were included in the cross-sectional study. Patients’
demographic characteristics and laboratory measurements are summarized in Table 1. Mean (SD) age at
inclusion was 41 (±10) years. There was a female (80%) and biopsy-proven type IV glomerulonephritis
(GMN) (76%) predominance. For 41 (58.6%) of patients, it was the first renal episode. The mean (SD)
of renal activity and chronicity indices were 7.5 (3.6) and 2 (1.9), respectively. Patients with active
nephritis were treated with standard therapy (see material and methods) and were followed for a
median of 6 years (range 1.5 to 8.5 years).
2.2. Urinary Expression of NRP-1 in Lupus Nephritis
Urinary NRP-1 mRNA levels in patients with active LN were significantly increased when
compared with other groups: SLE patients with active disease without renal involvement (30.70 ± 111.8
vs. 1.03 ± 0.94 relative expression; p = 0.01), other glomerular diseases (3.35 ± 3.65 relative expression;
p = 0.03), and healthy controls (1.03 ± 0.95 relative expression; p = 0.02) (Figure 1A). Among patients
with active LN, there were no differences in NRP-1 levels according to histological type or the degree
of disease activity.
2.3. Protein Levels of NRP-1 in Patients with Lupus Nephritis
In line with mRNA expression levels, patients with active LN had significantly higher
urinary NRP-1 levels, as measured by ELISA, than lupus patients with active non-renal disease
(1807 ± 2180 ng/mg Cr versus 95.26 ± 160.3 ng/mg Cr, p < 0.0001), patients with other glomerular
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diseases (1807 ± 2180 ng/mg Cr versus 13.11 ± 17.77 ng/mg Cr, p < 0.0001) and healthy controls
(1807 ± 2180 ng/mg Cr versus 59.14 ± 26.39 ng/mg Cr, p < 0.0001) (Figure 1B). Levels of uNRP-1
(area under curve = 0.956) showed a sensitivity of 85.71% and specificity of 90.24% to discriminate
active nephritis from active non-renal lupus disease (cut-off >293.55, Figure S1). Correlation analysis
of uNRP-1 levels with other clinical and laboratory parameters only showed a correlation with C4
levels (r = −0.182, p = 0.045, Figure 1C). Higher urine levels of NRP-1 did not correlate with type IV
glomerulonephritis or the degree of proteinuria, biopsy activity index, or urinary sediment. However,
an inverse correlation with nephritic flare was found (r = −0.246, p = 0.043, Figure 1C). Measurement
of serum NRP-1 levels did not show differences between groups (Figure S1).
Table 1. Clinical and histological variables at the time of the renal biopsy.
Characteristics Active LupusNephritis (n = 70)
Active
Non-Renal
SLE (n = 25)
Other
Glomerular
Diseases (n = 25)
Healthy
Controls (n = 25) p Value
a
Demographic
Age, yrs 41 ± 10 34 ± 6 35 ± 5 30 ± 4 0.4857 (0.787)[0.885]
Gender
(Female/male) 56/14 21/4 16/9 16/9
0.112 (0.723)
[0.112]
Race/ethnicity, n (%)
White Hispanic 65 (93)4 (6)
22 (88)
2 (8)
23 (92)
1 (4)
22 (88)
2 (8)
0.966 (0.966)
[0.500]
Other 1 (1) 1 (4) 1 (4) 1 (4)
Laboratory
parameters
Serum creatinine,
mg/dL 1.1 ± 0.5 0.8 ± 0.1 1.9 ± 0.8 0.8 ± 0.3
0.035 (0.006)
[0.001]
eGFR (mL/min) 82 ± 30 104 ± 16 48 ± 36 95 ± 22 0.091 (0.001)[0.006]
Urea (mg/dL) 54 ± 29 34 ± 14 81 ± 48 28 ± 11 0.076 (0.152)[0.012]
Anti-dsDNA Abs,
IU/mL 287 ± 68 39 ± 29 n.a. n.a. (0.087)
Serum C3, mg/dL 78 ± 31 94 ± 20 n.a. n.a. (0.101)
Serum C4, mg/dL 12.8 ± 9.2 13.4 ± 10 n.a. n.a. (0.090)
Proteinuria, g/24 h 3.3 ± 3.0 0.2± 0.1 9,1 ± 4,8 n.a. (0.010) [0.001]
Leukocytes (cel/µL) 95 ± 114 n.a. n.a. n.a.
Erythrocytes
(cel/µL) 133 ± 131 n.a. n.a. n.a.
Disease index
(SLEDAI-2K)
Total score 16 ± 2 8 ± 2 n.a. n.a. (0.006)
Renal score 12 ± 1 0 n.a. n.a.
Extra-Renal score 4 ± 2 8 ± 2 n.a. n.a. (0.001)
Renal Flare, n (%)
Proteinuric 59 (84) n.a. n.a. n.a.
Nephritic 11 (16) n.a. n.a. n.a.
First flare 41 (59) n.a. n.a. n.a.
Relapsing flare 29 (41) n.a. n.a. n.a.
Renal Biopsy, n (%)
Class III 9 (13) n.a. n.a. n.a.
Class IV 53 (76) n.a. n.a. n.a.
Class V 8 (11) n.a. n.a. n.a.
Activity Index 7.5 ± 3.6 n.a. n.a. n.a.
Chronicity Index 2.0 ± 1.9 n.a. n.a. n.a.
Values are expressed as mean ± standard deviation (SD). BUN, blood urea nitrogen; eGFR, estimated glomerular
filtration rate; anti-dsDNA, anti-double-stranded DNA (reference range <15 UI/mL); n.a., not applicable. a p-value
refers to the comparison of the active lupus nephritis (LN) with healthy controls, the values in bracket referred to
the comparison with active non-renal SLE and the values in square bracket referred to the comparison with the
cohort of other glomerular-diseases: Mann-Whitney U Test or Pearson χ2 test.
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Figure 1. Urinary NRP-1 relative expression levels (a) and concentrations (b) in active LN patients
compared with active SLE patients without renal disease, with other glomerular diseases and healthy
controls. Urinary biomarker expression levels (c) and concentrations (d) were measured according
to clinical response to therapy (responders vs non-responders). Biomarker concentrations were
standardised to urinary creatinine and expressed as median values. Horizontal line means median
value for each group. One-way ANOVA followed by Bonferroni test (a,b) and Student’s t-test (d) were
used to to compare biomarker concentrations between groups. * p < 0.05; *** p < 0.0001.
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2.4. Baseline Levels of NRP-1 Predict Clinical Response
Of the 70 included patients, 38 (54%) achieved complete response within a median of 18.5 months
(range: 2 to 65). Table 2 shows the baseline characteristics between responders and non-responders.
Non-responders had significantly higher levels of serum creatinine, more nephritic flares and relapsing
disease when compared with responders (p = 0.02, p < 0.0001, and p = 0.02, respectively). Measurement
of NRP-1 at inclusion showed responders to have higher urinary mRNA levels of NRP-1 than
non-responders (102 ± 210 vs. 8 ± 18 relative expression, p = 0.002) (Figure 1C). Differences were more
significant at a protein level (2532 ± 2439 ng/mg Cr vs. 569 ± 851 ng/ mg Cr, p < 0.0001) (Figure 1D).
Table 2. Baseline characteristics of patients according to clinical response to immunosuppressive therapy.
Characteristics
Responders Non-Responders
Active LN Cohort (n = 38) Active LN Cohort (n = 32) p Value
Demographic
Age (years) 42 ± 12 39 ± 8 0.517
Gender (Female/male) 33/5 27/5
Race/ethnicity, n (%)
White 35 (92) 30 (94) 0.811
Hispanic
Other
2 (5)
1 (3)
2 (6)
0
Laboratory parameters
Serum creatinine, mg/dL 1.0 ± 0.4 1.3 ± 0.6 0.025
eGFR (mL/min) 88 ± 26 75 ± 33 0.167
Urea (mg/dL) 48 ± 27 61 ± 30 0.054
Anti-dsDNA Abs, IU/mL 344 ± 84 220 ± 68 0.781
Serum C3, mg/dL 77 ± 32 79 ± 29 0.878
Serum C4, mg/dL 12.0 ± 9.6 13.7 ± 8.8 0.248
Proteinuria, g/24 h 3.0 ± 3.2 3.4 ± 2.7 0.563
Leukocytes (cel/µL) 95 ± 114 101 ± 190 0.495
Erythrocytes (cel/µL) 133 ± 131 187 ± 397 0.158
Disease index (SLEDAI-2K)
Total score 14 ± 3 15 ± 2 0.145
Renal score 10 ± 2 9 ± 3 0.112
Extra-Renal score 5 ± 3 4 ± 2 0.184
Renal Flare, n (%)
Proteinuric 38 (100) 14 (44) <0.0001
Nephritic 0 18 (56) <0.0001
First flare 27 (71) 14 (44) 0.021
Relapsing flare 11 (29) 18 (56) 0.021
Renal Biopsy, n (%)
Class III 4 (11%) 3 (9%) 0.714
Class IV 29 (76%) 26 (82%) 0.618
Class V 5 (13%) 3 (9%) 0.441
Activity Index 7.4± 3.2 7.6 ± 4.0 0.864
Chronicity Index 1.7 ± 2.1 2.2 ± 1.8 0.203
Values are expressed by means ± standard deviation (SD). eGFR, estimated glomerular filtration rate; anti-dsDNA,
anti-double-stranded DNA (reference range <15 UI/mL). p-value refers to the comparison of the Responders with
Non-Responders in combined cohorts by Mann-Whitney U Test or Pearson χ2 test.
Next, we performed receiver operating characteristic analyses to determine the best cutoff that
had the maximal sensitivity and specificity to predict clinical response. A urinary NRP-1 cutoff level of
1143 ng/mg Cr at baseline could predict clinical response with a sensitivity of 87.10%, specificity of
71.79% and a negative and positive predictive value of 87.50% and 71.05%, respectively (Figure 2A).
Patients with higher uNRP1 baseline levels had a significantly increased probability to achieve CR
(p < 0.0001, by log-rank test) (Figure 2B).
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A new prospective cohort (n = 39) (cohort 3) (22 responders and 17 non-responders) was 
established. Serial measurements of urine NRP-1 and VEGFA levels were performed three-monthly 
from baseline up to twelve months (Table 3). During follow-up, NRP-1 levels remained markedly 
increased in the responder group (median levels 1112 ng/mg Cr, p = 0.003), when compared with 
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Figure 2. Urinary Levels of NRP-1 and vascular endothelial growth factor (VEGFA) in active LN.
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biopsy g nerated from the optimal binary logistic regression model when data from both cohorts were
combined to discriminate between resp nders and non-resp nders. AUC = area under the ROC curv .
(b) Kaplan-Meier surviv l curve for clinical response following treatment among p tie ts with active
LN at the time of renal biopsy. Long rank test was used for analysis. p-valu ≤ 0.05 were consid red
significant. (c) Creatinine-normalized urine levels of VEGFA in combined cohorts of responders (n = 38)
and non-responders (= 32); *** p < 0.0001. (d) Correlation plot of urinary NRP-1 and VEGFA levels
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2.5. VEGFA, VEGFR1, VEGFR2, and SEMA3A in Patients with Lupus Nephritis and Correlation with
NRP-1 Levels
As there is a functional relationship between NRP-1 and the VEGF and the semaphorine family,
we measured the urinary mRNA and protein levels of VEGFA, VEGFR1, VEGFR2, and semaphorine3A
(SEMA3A). Urinary gene expression levels did not differ between patients with active LN when
compared with control groups, nor between responders and non-responders. However, urinary
VEGFA levels, measured by ELISA, were significantly increased in patients with active LN compared
with active SLE patients without renal disease and healthy controls (p = 0.01 and p < 0.0001, respectively)
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(Figure S2A). In contrast, urinary SEMA3A levels were significantly decreased in patients with active
LN when compared to the same control groups (p = 0.002 and p = 0.007, respectively) (Figure S2B).
There were no differences in urinary VEGFR1 and VEGFR2 levels (Figure S2C,D). When responders
were compared with non-responders, mirroring NRP-1 levels, responders had significantly higher
levels of urinary VEGFA compared with non-responders (166 ± 9 vs. 87 ± 7 ng/mg Cr, p < 0.0001)
(Figure 2C). No differences in urinary VEGF receptors and SEMA3A levels were found between
responders and non-responders (Figure S3).
There was a direct correlation between urinary VEGFA and NRP-1 protein levels (r = 0.466,
p < 0.0001, Figure 2D). However, VEGFA levels (12.34 ng/mg) showed an inferior profile to predict
response with a sensitivity and specificity of 71% and 75%, respectively (Figure S4). ROC analysis
comparing NRP-1 with baseline urinary VEGFA levels and other clinical factors such as creatinine and
proteinuria levels as predictors of response continued to show uNRP-1 levels to be an independent
predictive factor of response (p = 0.003) (Figure 2E).
2.6. Immunohistochemistry Localization of NRP-1, VEGFA and SEMA3A within Renal Biopsies
NRP-1 and VEGFA stained with a significantly higher intensity in the active LN group when
compared to the control group (Figure 3A). NRP-1 expression was mostly observed in the glomeruli
and along the tubuli. In the glomeruli, it was mostly expressed in the endothelial cell membrane
and in mesangial cells. Globally, NRP-1 expression was three times higher in responders than in
non-responders. There was a clear difference in the glomeruli staining, with responders having much
higher expression of NRP-1 (p < 0.0005). This difference was not observed in the tubuli (Figure 3A).
Renal NRP-1 protein levels correlated with urinary levels (p = 0.002, r = 0.834). VEGFA was highly
expressed in the glomeruli and tubular epithelial cells, but staining intensity did not differ between
responders and non-responders. Finally, semaphorine 3A staining was increased in patients with active
LN when compared to controls and expressed strongly in the tubuli of non-responders (Figure 3A).
2.7. Serial Monitoring of uNRP-1 Levels to Predict Response
A new prospective cohort (n = 39) (cohort 3) (22 responders and 17 non-responders) was established.
Serial measurements of urine NRP-1 and VEGFA levels were performed three-monthly from baseline
up to twelve months (Table 3). During follow-up, NRP-1 levels remained markedly increased in the
responder group (median levels 1112 ng/mg Cr, p = 0.003), when compared with non-responders
(median levels 149.1 ng/mg, Figure 3B). VEGFA levels during the first 6 months of follow-up were
significantly increased when compared to non-responders (levels 303 vs. 88 pg/mg, p = 0.05), but
afterwards, levels remained similar in both study groups (around 100–80 pg/mg, Figure 3C).
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Immunohistochemistry for NRP-1 and VEGFA in kidney biopsy (×400). Average scores were 
obtained for the evaluation of Vall Hebron pathologists group. (b) Changes in urinary protein levels 
of NRP-1 and VEGFA. (c) over the 12-month period of treatment in patients with LN. Dots and bars 
show means and SEM of protein levels in urine samples from baseline though the twelve months of 
follow-up. *p < 0.05. 
2.8. NRP-1 Expression Levels by Primary Cells under Stimulatory Conditions 
To establish a link between inflammation and NRP-1 production, primary renal cells were 
stimulated by inflammatory cytokines such as IL1-α and VEGF. At 24 h, following IL1-α stimulation, 
NRP-1 expression levels were significantly increased in mesangial renal cells when compared to the 
Figure 3. High levels of NRP-1 protein were confirmed in Responders vs Non-Responders.
(a) Immunohistochemistry for NRP-1 and VEGFA in kidney biopsy (×400). Average scores were
obtained for the evaluation of Vall Hebron pathologists group. (b) Changes in urinary protein levels
of NRP-1 and VEGFA. (c) over the 12-month period of treatment in patients with LN. Dots and bars
show means and SEM of protein levels in urine samples from baseline though the twelve months of
follow-up. * p < 0.05.
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Table 3. Baseline characteristics of prospective cohort of patient according to clinical response to
immunosuppressive therapy.
Characteristics Responders (n = 22) Non-Responders (n = 17) p Value
Demographic
Age (years) 42 ± 13 38 ± 9 0.198
Gender (Female/male) 17/5 8/9
Race/ethnicity, n (%)
White 21 (95) 14 (82) 0.193
Hispanics 1 (5) 3 (18)
Laboratory parameters
Serum creatinine, mg/dL 1.0 ± 0.7 1.3 ± 0.6 0.026
eGFR (mL/min) 88 ± 26 79 ± 33 0.172
Urea (mg/dL) 51 ± 27 61 ± 30 0.074
Anti-dsDNA Abs, IU/mL 324 ± 89 280 ± 85 0.819
Serum C3, mg/dL 75 ± 28 78 ± 30 0.941
Serum C4, mg/dL 12.4 ± 9.0 13.2 ± 8.7 0.637
Proteinuria, g/24 h 3.4 ± 3.1 3.3 ± 2.9 0.266
Leukocytes (cel/µL) 105 ± 114 101 ± 150 0.214
Erythrocytes (cel/µL) 183 ± 121 159 ± 197 0.431
Disease index (SLEDAI-2K)
Total score 14 ± 3 15 ± 2 0.092
Renal score 10 ± 2 9 ± 3 0.249
Extra-Renal score 5 ± 3 4 ± 2 0.142
Renal Flare, n (%)
Nephritic 0 11 (65) 0.082
Proteinuric 22 (100) 6 (35) 0.082
First episode 13 (59) 7 (41) 0.107
Relapsing 9 (41) 10 (59) 0.107
Renal Biopsy, n (%)
Class III 3 (14) 2 (12) 0.212
Class IV 15 (68) 12 (71) 0.966
Class V 4 (18) 3 (18) 0.791
Activity Index 7.0± 3.4 7.4 ± 3.8 0.936
Chronicity Index 1.5 ± 2.0 2.0 ± 1.5 0.377
Values are expressed as mean ± standard deviation (SD). eGFR, estimated glomerular filtration rate; anti-dsDNA,
anti-double-stranded DNA (reference range <15 UI/mL). p-value refers to the comparison of the Responders with
NonResponders cohorts: Mann-Whitney U Test or Pearson χ2 test.
2.8. NRP-1 Expression Levels by Primary Cells under Stimulatory Conditions
To establish a link between inflammation and NRP-1 production, primary renal cells were
stimulated by inflammatory cytokines such as IL1-α and VEGF. At 24 h, following IL1-α stimulation,
NRP-1 expression levels were significantly increased in mesangial renal cells when compared to
the other cellular types (p < 0.0001). However, following VEGF stimulation, endothelial renal cells
exhibited the highest expression levels of NRP-1. Under stimulation, T cells reduced significatively the
NRP-1 expression (Figure 4A).
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Figure 4. NRP-1 induced proliferation and migration in HRECs. (a) Expression levels of NRP-1
after non-stimulation (NS), interleukin-1 alpha (IL1-a) and vascular endothelial growth factor (VEGF)
stimulation in primary human cells: renal mesangial cells (HRMCs), renal endothelial cells (HRECs), T
cells and renal tubular epithelial cells (RTECs). One-way ANOVA (correction Bonferroni). *** p < 0.0001.
(b) Proliferation assay in inhibited NRP-1 and control with VEGF stimulation or with non-stimulation
conditions (NS). Student’s t-test. *** p < 0.0001 (c) A straight scratch was performed to simulate a
wound. After that, the distance between wound edges was determinate overtime and in each condition.
Migration rate was expressed as percentage of confluence index (CI) between the performed scratch and
calculated using the distance between wound edges. Photographs were captured by a phase contrast
microscope. Bars, 2 mm (d) Analysis of mRNA expression levels between inhibited NRP-1 HRECs in
VEGF or NS conditions. Fold change was calculated over their transfection control. Student’s t-test.
*** p < 0.0005 (e) Immunofluorescence of VEGFR2 (green) and NRP1 (red) in HRECs after transfection
and stimulation. Bars, 50 µm. DAPI staining was used to label cell nuclei. Student’s t-test. * p < 0.05.
HRECs: Human Renal Endothelial Cells.
2.9. Effect of NRP-1 on Endothelial Proliferation and Migration
To further investigate the role of NRP-1 in LN and its contribution to renal recovery by enhancing
angiogenesis, we inhibited NRP-1 in primary human renal endothelial cell (HREC) and performed
proliferation, migration and wound-healing assays. A significant downregulation of HREC cell
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proliferation was observed in NRP-1 inhibited HREC cells regardless of VEGF protein presence
(Figure 4B). In addition, no further HREC cell migration was observed beyond 24 h (p < 0.001, Figure 4C).
VEGFR2 and PI3K expression levels were significantly upregulated in inhibited NRP-1 HERC following
VEGF protein stimulation (5.8 and 3.3 fold change, respectively, Figure 4D). However, low levels of
NRP-1 and VEGFR2 protein were observed in NRP-1 inhibited HREC cells by immunofluorescence
(Figure 4E). Data suggest NRP-1 angiogenesis effect to be through a VEGF-dependent pathway.
2.10. NRP-1 Induces Migration in Human Renal Mesangial Cells Via PDGFB
Production of inflammatory cytokines and proliferation assays were evaluated in inhibited NRP-1
human renal mesangial cells (HRMCs). Following VEGF stimulation, no significant differences in
IL6, IL8, and CCL2 gene expression were observed between inhibited NRP-1 HRMCs and controls
(Figure S5A). Neither changes in proliferation were observed (Figure S5B). NRP-1 is a versatile
transmembrane coreceptor for VEGFA and also of PDGFB, known for its chemotactic effect on HRMC.
Therefore, we investigated whether NRP-1 is required for HRMC migration using in vitro Transwell
migration assay following PDGFB stimulation (Figure S6A). A significant reduction of relative cell
migration was observed in inhibited NRP-1 HRMCs following PDGFB stimulation (fold migration of
−3.11, p < 0.001, Figure 5A). This reduction was not observed in non-stimulatory conditions (Figure 6.
So, under PDGFB stimulation, NRP-1 gene expression is necessary to induce HRMC migration.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 13 of 20 
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were used to analysis the percentage of dead, apoptotic and live cells in primary human T cells after
VEGF stimulation. In inhibited NRP-1 T cells, only live cells were observed. *** p < 0.0005.
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2.11. NRP-1 Induces a VEGF-Dependent T cell Cytotoxicity
VEGF directly suppresses T cell activation via VEGFR2, and NRP-1 is a coreceptor of VEGFR2.
So, NRP-1 may have an immune suppression effect in T cells localized in LN kidneys. We inhibited
the NRP-1 gene expression from peripheral T cells isolated from patients with LN. Following VEGF
stimulation, no significant difference was observed in T cell activation (data not shown). However,
VEGF induced a significant cytotoxicity in control CD4+ T cells and CD8+ T cells not observed in
inhibited NRP-1 T cells (48–58% vs 0.1–0.2% death cells, respectively, p < 0.0001, Figure 5B). Data
suggest significantly increased VEGF-dependent T cell death in the presence of NRP-1.
3. Discussion
Attainment of complete remission in lupus nephritis is associated with significantly improved
prognosis and flare rate reduction [23]. Despite improvements in early diagnosis, close monitoring,
and intensive treatment, only a small proportion of patients will achieve remission. Several clinical
and histological factors have been associated with bad prognosis and progression to ESRD [24,25].
However, to date, current biomarkers are not reliable in predicting treatment response. The present
study shows NRP-1 as a biomarker of active LN and verifies its potential utility as an early biomarker
of therapeutic response.
This is the first study showing urinary NRP-1 both at a protein and gene expression level to be
significantly increased in patients with active lupus nephritis. NRP-1 urinary levels could discriminate
active renal disease from non-active disease with a sensitivity and specificity of 73.33% and 97.5%,
respectively, suggesting that its measurement is useful in diagnosis and a reliable marker of renal
disease activity in patients with SLE. NRP-1 deposits were also increased in the glomeruli of patients
with active renal disease when compared with normal kidneys and correlated with urinary NRP-1
levels. Vasdaz et al. had previously reported high levels of NRP-1 in the renal tissue of patients with
LN [22]. The study showed a positive correlation between NRP-1 levels and the clinic-pathological
parameters of renal disease. In addition, they observed a higher intensity of staining in patients with
focal GMN compared with those with diffuse GN, suggesting that NRP-1 could serve as a biomarker
to distinguish both types of glomerulonephritis [22]. Unlike that study, we could not find differences
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between the different histological types of LN but our study was not powered to see differences
between the subgroups. In view of the relationship between NRP-1, VEGF and the semaphorine family,
VEGF and semaphorine 3A levels were also analyzed in patients with active LN. In agreement with
Vasdaz et al. [22], we found that patients with active LN had increased VEGF levels in urine and renal
tissue that correlated with NRP-1 levels. Like in their study, semaphorine 3A staining was increased
in active LN and observed predominantly in the renal tubuli but in our study urinary levels were
significantly reduced in patients with active disease There is no data available on levels of semaphorine
3A in lupus nephritis to compare. Studies on serum and plasma had shown semaphorine 3A levels to
be decreased in patients with lupus disease compared to controls. Levels were found to be inversely
correlated with disease activity, mainly in the presence of lupus nephritis [20,21].
Baseline levels were also found to be a useful predictor of clinical response following therapy.
Responders had significantly higher urinary NRP-1 levels as well as during follow-up when compared
with non-responders. NRP-1 renal expression was also increased in responder patients and found
predominantly in the glomeruli unlike the non-responders. Mirroring NRP-1 levels, responders had
also significantly increased VEGF urinary levels but no differences in renal staining were found between
the groups. Conversely, responders showed a decreased semaphorine 3A renal staining compared
to non-responders in which semaphorine 3A was strongly expressed in the tubuli. Previous studies
have already suggested a role for Semaphorine 3A in renal damage [22]. There were no differences in
urinary semaphorine 3A levels. After analyzing the predictive value for CR amongst several predictive
factors, urinary NRP-1 levels at the time of renal biopsy were found to be an independent factor of
clinical response and responders had persistently increased levels during follow-up. Whereas this is
the first time that the prognosis value of NRP-1 is shown, the prognosis value of VEGF in LN has been
previously reported [26]. Decreased renal expression was associated with worse prognosis, serving as
a molecular marker of renal damage and a short-term loss of kidney function in those patients.
To date, little is known concerning the involvement of NRP-1 in SLE, and even less about its role
in LN. There are still some open questions, whether this molecule is pathogenic or to some extent
protective. Although the exact mechanism is not well known, our data support that NRP-1 along with
VEGF and semaphorine are proteins involved in LN and have an important role in renal recovery.
NRP-1 serves as a receptor for VEGF. Several studies have suggested that VEGF plays a key
protective role by maintaining normal glomerular homeostasis and the integrity of glomerular
endothelial cells [15,19]. Our in vitro studies show a link between inflammation and production of
NRP-1 by the primary renal cells. The production is clearly influenced by the predominant inflammatory
cytokine in the environment. So, following IL1 stimulation, NRP-1 was mainly produced by mesangial
cells, whereas following VEGF, endothelial cells were the one showing stronger expression levels
of NRP-1. Since high levels of NRP-1 were found in therapeutic responders, it suggests a role for
this molecule in renal repair. The in-vitro studies describe different mechanisms by which NRP-1
may have this role. Our study demonstrates that NRP-1 enhances VEGF activity, intensifying its
protective effect by increasing its angiogenic activity (Figure 6). Proliferation of new blood vessels
and consequently a greater oxygen supply in the glomerular endothelium provide the environment
to enhance renal recovery [27]. On the other hand, we observed that inhibition of NRP-1 decreased
migration of human mesangial renal cells in a PDGFB-dependent pathway. This indicates that NRP-1
is required for cell motility signaling driven by PDGFB. Migration of mesangial cells is important
in repair and maintenance of the mature glomerulus [28,29]. Finally, VEGF suppresses activation
of T cells via VEGFR2 [30,31]. In our work, we demonstrated that in inhibited NRP-1 cells, VEGF
stimulation did not provoke T cell death. Conversely, VEGF promoted T cell death in the presence of
NRP-1. A high amount of CD8+ T cells have been shown in the renal biopsies of patients with LN in
comparison with other T cell subsets such as CD4+ or Treg cells [32]. NRP1 receptor has been described
in CD8+ T cells [33]. However, we did not see differences in the dead cellular rate between CD4+ and
CD8+. In view of these results, we hypothesized that high levels of NRP-1 in the presence of VEGF
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could increase T-cell death, which in turn could decrease the inflammatory and cytotoxicity renal state
as a first step to renal recovery (Figure 6).
The main limitations of the study are its single-center nature and the relatively short period of
follow-up in the longitudinal study. Validation in a larger prospective cohort is therefore necessary.
Further investigation of the role of NRP-1 in animal models will help to understand its role in
renal repair.
In conclusion, our results demonstrate that urinary and renal NRP-1 levels at the time of renal
flare may serve as a novel prognostic biomarker for prediction of clinical response in lupus nephritis.
4. Materials and Methods
4.1. Patients
We established an initial exploratory cross-sectional cohort (n = 25) followed by a validation
cohort (n = 45). For the purpose of the study both cohorts were combined and presented as the primary
cohort of patients with LN (n = 70). Details of the two different cohorts are shown in SI (Supplementary
Tables S1 and S2). In addition, a new prospective cohort of patients with active LN (n = 39) was also
established. Active lupus nephritis was defined by either a total urinary protein level ≥0.5 g/day,
an increment of serum creatinine levels of more than 0.5 mg/dL or the presence of active sediment
by microscopic examination, and confirmed by renal biopsy. All patients fulfilled at least 4 of the
American College of Rheumatology (ACR) revised classification criteria for SLE [34]. SLE disease
activity was assessed by the SLE Disease Activity Index 2000 update (SLEDAI-2Ks; range 0–105) [35].
Renal SLEDAI refers to the sum of the SLEDAI-2Ks accrued in the renal domain of the measure
(rSLEDAIs; range 0–16). All patients were treated with IV methyl-prednisolone (500 mgx3) followed
by a tapering dose of oral prednisone along with at least a 24-month course of oral mycophenolate
mofetil. Results were also analyzed according to clinical outcome after treatment (responders (n = 38)
vs. non-responders (n = 32). Following therapy, complete response (CR) was defined as urinary
protein excretion <0.2 g/24 h, normal urinary sediment and normal or stable renal function (within
10% of normal eGFR if previously abnormal renal function). No clinical response was defined by a
urinary protein excretion ≥0.2 g/24 h, increase in the serum creatinine concentration ≥0.6 mg/dL, a
creatinine clearance >15% below the baseline value discontinuation of treatment due to side effects or
renal relapse while on full treatment [36].
More information about renal flare [37] kidney biopsy evaluation [24,38] and, treatment [39] in
Supporting Information.
Urine and blood samples were collected from each patient 1 day before renal biopsy and processed
immediately to be stored at −80 ◦C. Patients with urinary tract infection, diabetes mellitus, pregnancy,
malignancy, and non-lupus-related renal failure were not included.
The control groups consisted of SLE patients with active disease (SLEDAI > 6) without renal
involvement (n = 25), healthy volunteers (n = 25) and patients with other glomerular diseases (n = 25)
(diabetic nephropathy (n = 12), IgA nephropathy (n = 4), idiopathic membranous nephropathy (n = 4),
and focal segmental glomerulosclerosis (n = 5) were also included.
The study was approved by the Vall d’Hebron Ethic Committee (Urinary Biomarkers LN,
22 April 2009) and written informed consent was obtained from all patients. More details about study
design in Supporting Information.
4.2. mRNA Isolation, cDNA Synthesis and Real-Time PCR
Urine samples were immediately centrifuged after collection at 3900× g for 30 min (4 ◦C) and
supernatant was stored at −80 ◦C. Total RNA was isolated from the cell pellets using the RiboPure
RNA Purification Kit (Ambion, Life Technology, Carlsbad, CA, USA) following the manufacturer’s
instructions. Quantification of NRP-1, VEGFA, VEGFR1, VEGFR2 and SEMA3A mRNA by TaqMan
Real-Time PCR was carried out as described by the manufacturer (ThermoFisher, Carlsbad, CA, USA).
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RNA was reverse-transcribed into cDNA using the High Capacity RNA-to-cDNA Kit and the
quantitative RT-PCR reaction was performed in 96-well plates on the ABI PRISM 7000HT. The data was
normalized based on the expression of the endogenous control GAPDH (more details in Supporting
Information).
4.3. Enzyme-Linked Immunosorbent Assay (ELISA)
Enzyme-linked immunosorbent assay (ELISA) was used to quantify urinary and serum levels of
NRP-1 (Cloud-Cone Corp, Katy, TX, USA), VEGFA (RayBiotech, Norcross, GA, USA), VEGFRI
(RayBiotech, Norcross, GA, USA), VEGFR2 (RayBiotech, Norcross, GA, USA), and SEMA3A
(Cloud-Cone Corp, Katy, TX, USA) following the manufacturer’s instructions. Triplicate for all
samples were done. Urinary levels were normalized against the corresponding urine creatinine levels.
4.4. Renal Histology and Immunohistochemistry
Paraffin sections were stained with haematoxylin and eosin, periodic acid-Schiff, trichrome,
and silver for light microscopy. The specimens were scored for activity and chronicity [24]. All
biopsies were examined by one pathologist that was not aware of the molecular study results.
For immunohistochemistry, formalin-fixed paraffin-embedded tissue sections were deparaffinized and
primary antibodies were incubated with slides overnight at 4 ◦C (more information in Supporting
Information). As controls, we used disease-free kidney sections from tissue margins of total or subtotal
nephrectomies obtained from patients undergoing surgery for renal malignancies.
4.5. Cell Cultures
Primary Human Renal Endothelial Cells (HRECs), Primary Human Renal Glomerular Mesangial
cells (HRMCs) and Primary Human Renal Tubular Epithelial cells (RTECs) were purchased and
cultured in the recommended media provided by the manufacturer (Innoprot, Derio, Bizkaia, Spain).
Isolated primary T cells were cultured in RPMI medium supplemented with 10% fetal bovine
serum (FBS) and 5% penicillin/streptomycin (more details in Supporting Information). Cells were
grown at 37 ◦C in a humidified 5% CO2 atmosphere. Cell passes were performed using TrypLETM
Express (ThermoFisher, Carlsbad, CA, USA).
4.6. NRP-1 Expression Levels in Primary Cells
Primary human cells (HRECs, HRMCs, RTECs and T cells) were platted onto 24-wells
(1 × 104 cells/mL). After 24 h, stimulation with IL-1 (10 ng/mL) or VEGF (50 ng/mL) cytokine
was performed during 24 h. PBS were added as control in non-stimulation conditions. After that, RNA
extraction was performed to analyze NRP-1 expression levels by real-time PCR.
4.7. NRP-1 Inhibiton and Stimulation Conditions
Primary human cells were cultured in their appropriate medium and at passage 2 were
plated onto 24-well or 96-well Cell+ culture plates (Sarstedt, Nümbrecht, Germany). After 24 h,
primary cells were confluence between 70–80% and they were transfected with gRNA NRP-1 or
their negative-control using LipofectamineTM CRISPRMAXTM Reagent Cas9 Nuclease Transfection
Protocol (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. After inhibition
of NRP-1, renal cells were stimulated with different conditions during 24 h: 50 ng/mL of
VEGF (Gibco®Thermofisher Scientific, Carlsbad, CA, USA), 50 ng/mL PDGFB (ThermoFisher,
Carlsbad, CA, USA) or Non-stimulation as negative control. After that, wound healing assay,
proliferation assay, apoptosis assay, immunofluorescence assay, or RNA extraction were performed.
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4.8. Wound Healing Assay
To perform wound healing assays, we used a scratch assay in primary cultured cells inhibiting
the NRP-1 gene and following stimulatory conditions. To calculate migration, we used the analysis of
bright field microscopic images by determining the distance between wound edges over time compared
to the control (more details in Supporting Information).
4.9. Proliferation Assay
After 24 h of stimulation, proliferation assays were performed using CyQUANT® NF Cell
Proliferation Assay Kit (ThermoFisher, Carlsbad, CA, USA) following the manufacturer’s instructions.
The diluted CyQUANT® NF dye reagent was added to every well and the fluorescence was measured
using a fluorescence microplate reader with excitation at 485 nm and emission detection at 530 nm.
4.10. Migration Assay
Migration assay was conducted using Boyden chambers with 8-µm-pore polycarbonate
membranes. The chambers were placed in culture wells in medium supplemented with PDGFB
stimulation or non-stimulation. Cells that migrated across the chamber membrane within 6 h were
stained with DAPI and quantified using immunofluorescence microscopy. At least, three independent
experiments were performed, and results of representative experiments were shown.
4.11. Apoptosis Assay
Apoptosis assay were carried out using Dead Cell Apoptosis Kith with APC annexin V and
SYTOX® Green Flow Cytometry (ThermoFisher, Carlsbad, CA, USA) following the manufacturer’s
instructions. Cells were stained using two fluorophores: Annexin V conjugated to allophycocyanin
(APC) to detect apoptotic cell and SYTOX Green dye to stain dead cells. After incubation during 15 min
at 37 ◦C, stained cells were analyzed by flow cytometry (BD LSRFortessa™, Haryana, India).
4.12. Immunofluorescence Assay
For immunofluorescence, cells were incubated with PFA 4% during 20 min. After washing
with PBS, they were incubated with 0.1% triton during 10 min. Blocking using PBS 5% BSA was
performed during 1 h at room temperature and primary antibody Rabbit pAb to VEGFR2 and NRP-1
Mouse monoclonal IgG (1:200, Santa Cruz Biotechnology, Dallas, TX, USA) were incubated overnight
at 4 ◦C. Secondary antibodies were incubated during 2.5 h at room temperature (more details in
Supporting Information).
4.13. Statistical Analysis
Raw threshold cycle (Ct) values were imported from ABI7000 SDS software and relative expression
levels for each mRNA were calculated using the comparative Ct method. Continuous variables were
compared using Student’s t-test or one-way ANOVA followed by Tukey’s multiple comparison test
when appropriate. Categorical data were compared by the Chi-square test. Spearman’s rank-order
correlation was used to analyze the correlation between two parameters. Time-to-event analyses
were performed with Kaplan-Meier method and log-rank test. The diagnostic performance of
biomarkers was evaluated by calculating their sensitivity and specificity using ROC curves. Cutoff
values were determined according to Youden’s index. A p value <0.05 was considered statistically
significant. Statistical analyses were performed by GraphPad Prism version 6 (GraphPad Software,
La Jolla, CA, USA) and SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/18/
4601/s1.
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